Dudediligence.

Perspective Therapeutics, Inc

CATXAMEX · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$15.1MSep ’24−$40.2MDec ’24−$18.2MMar ’25−$21.5MJun ’25−$26.0MSep ’25−$37.5MDec ’25−$26.2MMar ’26−$26.8MJun ’26
Fiscal years, by the month each ended
LineDec 2022Dec 2023Dec 2024Dec 2025Jun 2026
Revenue$0.00$1.4Mnone on filenone on filenone on file
Gross profit$0.00$1.4Mnone on filenone on filenone on file
Operating income−$8.7M−$40.9M−$90.9M−$113.6Mnone on file
Net income−$10.8M−$46.5M−$79.3M−$103.1Mnone on file
Operating cash flow−$10.4M−$36.9M−$18.3M−$82.5Mnone on file
Free cash flow−$10.7M−$38.0M−$72.7M−$95.2Mnone on file
Cash$21.0M$9.2M$61.6M$30.6M$48.5M
Debtnone on file$1.7M$1.7M$1.6M$1.6M
Shares outstanding142.1M28.2M70.7M74.3M114.1M